Avid Bioservices Inc (CDMO)

[pacemakernj]

Feuerstein Ratain Rule states "after looking at outcomes of 58 phase 3 cancer trials over the past 10 years the pair found the companies with market caps less than $300 milliom several months before the release of trial results were 0-21. Whereas companies with a market cap exceeding $1 billion were a respectable 21-27. Ouch!"

Humm upon further review I would like to mention that the current market cap of PPHM is $282.31 million. So if PPHM share price were to rise just $.15 and hold above there let's just say $2.30, would this negate the rule and give Messers Feuerstein and Ratain their out should PPHM get their partner? We would afterall have a market cap above $300 million. Just asking.

What about companies between $300 million and $1 billion? What does their reserach say on that? While this latest attempt to draw conclusions about PPHM's future failure have been rebuffed. We ALL know that past performance is no guarantee of future results. The stock market and stocks are about probabilities and possibilities.

I think PPHM's performance yesterday speaks for itself. It regarded this latest attempt to trash the stock by drawing conclusions about previous biotech stocks as not relevant. AF can claim victory either way. It is sneaky business we are in. AF should know better. All imho.

Pacemaker